Form 4: VolitionRx CCO Tax Withholding on RSU Settlement

VolitionRx's Chief Commercial Officer, Gael Forterre, reported a routine tax withholding of 2,010 shares related to restricted stock unit settlement.

Summary

• Gael Forterre, Chief Commercial Officer of VolitionRx Ltd (VNRX), reported a transaction on February 1, 2026.
• The transaction involved the disposition of 2,010 shares of common stock at a price of $0.285 per share.
• These shares were retained by VolitionRx for cancellation to satisfy tax withholding obligations upon the settlement of 4,863 restricted stock units (RSUs).
• The RSUs were awarded to Mr. Forterre in lieu of cash compensation.
• No shares were sold by Mr. Forterre or VolitionRx in this transaction.
• Following the transaction, Mr. Forterre directly beneficially owns 189,872 shares, indirectly owns 5,000 shares through his spouse, and indirectly owns 32,500 shares through Armorica Partners, LLC.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves a disposition of shares, it's for tax purposes on RSU settlement, not an open market sale, suggesting no negative insider sentiment.

Positives

• The transaction is a routine tax withholding, not an open market sale by the insider, indicating no direct negative sentiment from the officer.
• The settlement of restricted stock units suggests ongoing compensation for the officer, which can be a positive for management retention.

Negatives

• A small reduction in direct beneficial ownership due to tax withholding, though not an open market sale.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider filings like this Form 4 are common across all industries as part of executive compensation and tax compliance, and typically do not reflect significant shifts in broader industry trends or competitive landscapes.

Related Party Transactions

• Gael Forterre, as managing director and sole shareholder of Armorica Partners, LLC, has voting and dispositive control over 32,500 shares held by Armorica Partners, LLC, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax withholding and not an open market sale by an insider. It confirms the ongoing compensation structure for a key executive.
• Employees: No direct impact mentioned.
• Customers, Suppliers, Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding transaction by a Chief Commercial Officer related to restricted stock unit settlement. It does not indicate any significant change in the company's fundamentals, strategic direction, or insider sentiment that would warrant a change in investment recommendation. The transaction is a standard part of executive compensation and tax compliance, thus a 'hold' recommendation is appropriate as it provides no new material information to alter an existing investment thesis.

Keywords

VolitionRx, VNRX, Gael Forterre, Chief Commercial Officer, Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Beneficial Ownership, Corporate Governance